Quantum biopharma announces that the safety review committee recommends commencing dosing of second cohort in the phase 1 multiple ascending dose clinical trial for lucid-21-302 (lucid-ms)

Toronto, on / accesswire / december 10, 2024 / quantum biopharma ltd. (nasdaq:qntm)(cse:qntm)(fra:0k91) ("quantum biopharma" or the "company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, huge biopharma australia pty ltd.
QNTM Ratings Summary
QNTM Quant Ranking